Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.

Trial Design

TROPHY WAS A PHASE 2, SINGLE-ARM, OPEN-LABEL, MULTICENTER TRIAL THAT STUDIED THE USE OF TRODELVY

Trial Design

*Assessed using Independent Review Assessment (IRA) based on RECIST 1.1.

Demographics and patient characteristics (N=112)1

  • Median age, years (range): 66 years (33–90 years)
  • 78% male; 74% White, 3% Asian, 3% Black, and 20% unknown
  • ECOG performance status: 0 (28%), 1 (72%)
  • 96% of patients had metastatic disease; 67% of patients had visceral metastases, including 34% with liver metastases
ECOG=Eastern Cooperative Oncology Group.

Patients received a median of 3 prior therapies (range: 1–8)1

TRODELVY® (sacituzumab govitecan-hziy) prior therapies chart

For 34% of patients, the platinum-containing chemotherapy was received in the neoadjuvant/adjuvant setting only.

Reference: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021.